Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?

Stefan Leucht, S. Z. Levine, M. Samara, A. Cipriani, J. M. Davis, T. A. Furukawa

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)621-623
Number of pages3
JournalEuropean Archives of Psychiatry and Clinical Neuroscience
Issue number7
StatePublished - 1 Oct 2018

Bibliographical note

Funding Information:
In the last three years Stefan Leucht received honoraria for consulting from LB Pharma, Lundbeck, Otsuka, TEVA, LTS Lohmann, Geodon Richter, Recordati, Boehringer Ingelheim, and Sandoz. For lectures from Janssen, Lilly, Lundbeck, Otsuka, SanofiAventis, Servier and Sunovion. Over 3 years ago, Dr Levine received honoraria and/or research support, and/or consultancy fees and/or travel support from: Shire Pharmaceuticals, F. Hoffmann-La Roche and Eli Lilly. Toshi A Furukawa has received lecture fees from Meiji, Mitsubishi-Tanabe, MSD and Pfizer. He has received research support from Mitsubishi-Tanabe. John M Davis and Myrto Samara have no conflict of interest to declare.

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Cite this